A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: a multicentric Italian experience

The European Medicines Agency strongly recommends administration of trabectedin through a central venous catheter (CVC) to minimize the risk of extravasation. However, CVCs place patients at risk of catheter-related complications and have a significant budgetary impact for oncology departments. The most frequently used CVCs are subcutaneously implanted PORT-chamber catheters (PORTs); peripherally inserted central venous catheters (PICCs) are relatively new. We reviewed data of trabectedin-treated patients to evaluate the relative cost-effectiveness of the use of PORTs and PICCs in six Italian centres. Data on 102 trabectedin-treated patients (20 with sarcoma, 80 with ovarian cancer and two with cervical cancer) were evaluated. Forty-five patients received trabectedin by a PICC, inserted by trained nurses using an ultrasound-guided technique at the bedside, whereas 57 patients received trabectedin infusion by a PORT, requiring a day surgery procedure in the hospital by a surgeon. Device dislocation and infections were reported in four patients, equally distributed between PORT or PICC users. Thrombosis occurred in a single patient with a PORT. Complications requiring devices removal were not reported during any of the 509 cycles of therapy (median 5; range 1–20). PICC misplacement or early malfunctions were not reported during trabectedin infusion. The cost-efficiency ratio favours PORT over PICC only when the device is used for more than 1 year. Our data suggest that trabectedin infusion by PICC is safe and well accepted, with a preferable cost-efficiency ratio compared with PORT in patients requiring short-term use of the device (⩽1 year).

[1]  B. Vincenzi,et al.  Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study. , 2013, Gynecologic oncology.

[2]  C. Sessa,et al.  Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors , 2013, Investigational New Drugs.

[3]  Nicoletta ColomboStan,et al.  Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials , 2013 .

[4]  B. Koczwara,et al.  Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies , 2013, Supportive Care in Cancer.

[5]  B. Monk,et al.  Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. , 2012, European journal of cancer.

[6]  J. Blay,et al.  A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials , 2012, Investigational New Drugs.

[7]  B. Monk,et al.  Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. , 2011, Gynecologic oncology.

[8]  B. Monk,et al.  Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  R. Salazar,et al.  Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors , 2012, Investigational New Drugs.

[10]  C. Galmarini,et al.  A Review of Trabectedin (ET-743): A Unique Mechanism of Action , 2010, Molecular Cancer Therapeutics.

[11]  B. Monk,et al.  Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Demetri,et al.  Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Provencher,et al.  A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens , 2007, British Journal of Cancer.